Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Journal article
Title: The neuroprotective properties of the amyloid precursor protein following traumatic brain injury
Author: Plummer, S.
Van Den Heuvel, C.
Thornton, E.
Corrigan, F.
Cappai, R.
Citation: Aging and Disease, 2016; 7(2):163-179
Publisher: International Society on Aging and Disease
Issue Date: 2016
ISSN: 2152-5250
Statement of
Stephanie Plummer, Corinna Van den Heuvel, Emma Thornton, Frances Corrigan, Roberto Cappai
Abstract: Despite the significant health and economic burden that traumatic brain injury (TBI) places on society, the development of successful therapeutic agents have to date not translated into efficacious therapies in human clinical trials. Injury to the brain is ongoing after TBI, through a complex cascade of primary and secondary injury events, providing a valuable window of opportunity to help limit and prevent some of the severe consequences with a timely treatment. Of note, it has been suggested that novel treatments for TBI should be multifactorial in nature, mimicking the body's own endogenous repair response. Whilst research has historically focused on the role of the amyloid precursor protein (APP) in the pathogenesis of Alzheimer's disease, recent advances in trauma research have demonstrated that APP offers considerable neuroprotective properties following TBI, suggesting that APP is an ideal therapeutic candidate. Its acute upregulation following TBI has been shown to serve a beneficial role following trauma and has lead to significant advances in understanding the neuroprotective and neurotrophic functions of APP and its metabolites. Research has focused predominantly on the APP derivative sAPPα, which has consistently demonstrated neuroprotective and neurotrophic functions both in vitro and in vivo following various traumatic insults. Its neuroprotective activity has been narrowed down to a 15 amino acid sequence, and this region is linked to both heparan binding and growth-factor-like properties. It has been proposed that APP binds to heparan sulfate proteoglycans to exert its neuroprotective action. APP presents us with a novel therapeutic compound that could overcome many of the challenges that have stalled development of efficacious TBI treatments previously.
Keywords: Amyloid precursor protein; traumatic brain injury; diffuse axonal injury; neuroprotection; heparan sulphate proteoglycans
Rights: Copyright status unknown
DOI: 10.14336/AD.2015.0907
Grant ID: ARC
Appears in Collections:Aurora harvest 7
Medical Sciences publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.